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Background: Transgenic Plasmodium falciparum expressing luciferase offers an attractive bioluminescence-based
assay platform for the investigation of the pharmacological properties of anti-malarial drugs. Here a side-by-side
comparison of bioluminescence and fluorescence-based assays, utilizing a luciferase reporter cassette that confers a
strong temporal pattern of luciferase expression during the S-phase of intraerythrocytic development, is reported.
Methods: Key assay parameters for a range of commercially available luminogenic substrates are determined and
compared to those measured using a Malaria Sybr Green I fluorescence assay. In addition, the short-term temporal
effects of anti-malarial compounds are evaluated using both bioluminescent and fluorescent assay platforms.
Results: The Z’, % coefficient of variation and 50% inhibition concentrations are essentially the same for
bioluminescent and fluorescent assays in transgenic parasites generated in both chloroquine-sensitive and -resistant
genetic backgrounds. Bioluminescent assays, irrespective of the luminogenic agent employed, do, however, offer
significantly enhanced signal-to-noise ratios. Moreover, the bioluminescent assay is more dynamic in terms of
determining temporal effects immediately following drug perturbation.
Conclusion: This study suggests that opportunities for bioluminescence-based assays lie not in the measurement
of 50% inhibition concentrations, where the cheaper fluorescence assay performs excellently and is not restricted
by the need to genetically modify the parasite clone under investigation. Instead, assays that use the dynamic
response of the luciferase reporter for semi-automated screening of additional pharmacological properties, such as
relative rate-of-kill and lethal dose estimation, are a more attractive development opportunity.
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Following the emergence and spread of multidrug resist-
ant Plasmodium falciparum and reports of artemisinin
treatment failure in South-East Asia, there is an urgent
need to identify new small molecule drugs for the treat-
ment of malaria [1,2]. Towards this aim, several recent
reports have described the high throughput screening
(HTS) of massive chemical libraries and the identifica-
tion of novel chemical scaffolds to be taken forward for
development [3-5]. Prioritizing these compounds for fur-
ther exploration of their pharmacokinetic and pharma-
codynamic properties is essential and has been the focus
of several recent developments in assay formats [6-10].* Correspondence: p.d.horrocks@keele.ac.uk
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distribution, and reproduction in any mediumAssays of anti-malarial drug activity typically rely on
either radiometric or fluorescence-based platforms. In-
corporation of tritiated hypoxanthine or ethanolamine
has been widely used as a biomarker for growth and of-
fers a sensitive assay with excellent signal/noise (S/N) ra-
tio [11]. There are, however, significant issues around
the safe storage and disposal of the radiolabelled mater-
ial. Fluorescence-based platforms, such as the use of the
DNA intercalating agents Sybr Green I or 40,60-diami-
dino-2-phenylindole (DAPI), offer a rapid, cheap and
sensitive assay but can be problematic due to the low S/
N ratio resulting from high background signals [12-14].
That said, the utility of the Malaria Sybr Green I Fluo-
rescence (MSF) assay for single-dose HTS has been readily
demonstrated.
A recent innovation has been the adoption of a bio-
luminescence assay platform that utilizes transgenicntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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The utility of bioluminescence has been demonstrated in
HTS of medium-sized chemical libraries, exploration of
gametocidal and delayed-death drug action, and the devel-
opment of a murine malaria assay in Plasmodium berghei
[15-20]. The use of bioluminescence to assay anti-malarial
drug activity in P. falciparum was first described in 2008
[17]. Here luc was flanked by the Pfhsp86 50 and Pbdhfr-ts
30 sequences and integrated as a short concatamer into
chromosome 7. The assay provided 50% inhibition con-
centration (IC50) results comparable to those determined
using 3H-hypoxanthine or MSF, with a subsequent re-
port demonstrating the feasibility of scaling the use
of this transgenic parasite into a 384-multiwell format
[16]. Screening the Library of Pharmacologically Ac-
tive Compounds (LOPAC1280) demonstrated the robust-
ness of this assay format with Z’ scores >0.7 and S/N ratio
of 71. In 2010, a second luc transgenic parasite with a
Pfhrp2 promoter was reported for the screening of three
chemical libraries, a total of 12,320 compounds, reporting
Z’ scores of 0.64-0.76 and S/N ratios of 147–430 [20]. The
increase in S/N ratio recorded here presumably represents
their choice of the Bright-Glo luminogenic substrate in
their assays. A final report describes the bxbI integrase-
mediated integration of a Pfhrp3-luc-Pfhrp2 cassette into
chloroquine-resistant (CQR) and –sensitive (CQS) genetic
backgrounds [18]. Whilst the bioluminescence assay data
correlated well with that generated using 3H-hypoxan-
thine and MSF for fast-acting drugs (Z’ score of 0.71 and
S/N of 51), the MSF assay appeared to provide poor re-
solving capacity when screening delayed-action drugs such
as azithromycin (Z’ scores <0.4 and S/N of 2–3).
The generation of a transgenic parasite where luc is
under the control of the 50 and 30 flanking sequences of
Pfpcna has previously been described [21,22]. These flank-
ing sequences have been shown to provide the regulatory
elements necessary to reconstitute the absolute and tem-
poral control of the endogenous Pfpcna gene on the luc re-
porter gene. Pfpcna encodes a processivity factor for DNA
polymerase δ and, as such, acts as a biomarker for DNA
replication in mature trophozoites during intraerythrocytic
schizogony [23]. This transgenic parasite shows a strong
20–50,000 fold-increase in luciferase signal in mature tro-
phozoites when compared to ring stage parasites, suggest-
ing that the matched Pfpcna 50 and 30 flanking sequences
confer a strong dynamic temporal control on luc [22].
Here an evaluation of the Pfpcna-luc transgenic parasite as
a tool to explore the action of anti-malarial drugs is des-
cribed along with a side-by-side comparison of this assay
with MSF in both CQS and CQR genetic backgrounds.
This study offers insights into the opportunities available
for bioluminescence assays to explore a range of pharma-
cological properties of anti-malarial drugs in a format rea-
dily scalable for high throughput assays.Methods
Plasmodium falciparum cell culture
The transgenic Dd2 P. falciparum clone expressing lu-
ciferase under the control of Pfpcna flanking sequences
(Dd2luc) has been previously described [21]. Dd2luc were
cultured using standard continuous culture conditions
(RPMI1640 medium supplemented with 37.5 mM HEPES,
10 mM D-glucose, 2 mM L-glutamine, 100 μM hypoxan-
thine, 25μgml-1 gentamycin and 8% v/v human serum) at
a 2% haematocrit in an atmosphere of 1% O2, 3% CO2,
and 96% N2. 5nM WR99210 and 2.5 μg/ml blasticidin S
drug selection was applied throughout. Staging and para-
sitaemia were determined by light microscopy of Giemsa-
stained thin blood smears. Synchronization of cultures
was attained using sequential sorbitol lysis treatment [24].
Generation of NF54luc transgenic parasite
NF54attB and pINTNeo were kindly provided by David
Fidock (Columbia University, New York). BxbI inte-
grase-mediated integration of the same Pfpcna-luc re-
porter construct present in Dd2luc was performed in
NF54attB as previously described, except that WR99210
selection was not applied as the hdhfr selection cassette
is omitted from NF54attB [21,25]. Integration was con-
firmed by absence of PCR over the cg6 locus, in which
the attB site is located (primers P1, 50ATGAACAAA
TACATAAGAGCGC30 and P2, 50TCTTTAATTTTA
TTTTGGTCATGC30), and generation of a PCR product
over the attL site (primers P1 and P3, 50TAAGGAGAA
AATACCGCATCAGG30) that results from attP × attB
recombination.
The reconstituted temporal control of Pfpcna expres-
sion over luc was shown by stage-specific northern blot
and luciferase assay. NF54luc was synchronized and sam-
ples removed at five points during asexual intraeryth-
rocytic development. These samples represented major
stages of morphological development as judged by light
microscopy; early rings (0–8 hours post-infection, hpi),
late rings (9-16hpi), early trophozoites (17-24hpi), late
trophozoites (25-36hpi) and schizonts (37-48hpi), ter-
med T1 to T5, respectively. Luciferase assays on T1 to
T5 were carried out as described below. For stage-speci-
fic northern blots, total RNA was isolated from samples
T1 to T5 and 5 μg of total RNA was size-fractionated,
blotted and hybridized to α-32P dATP random-primer
labelled probes to the luc and Pfpcna genes. Images were
captured using the Cyclone Storage Phosphor screen ap-
paratus (Packard) and analysed using OptiQuant soft-
ware (Packard).
Standard luciferase assay procedure and time course
A standard single-step lysis procedure was used through-
out [22]. Forty μl samples of P. falciparum culture (typic-
ally at 2% haematocrit, HCT) were transferred to a well
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passive lysis buffer (Promega, UK) added and homoge-
nized by shaking the plate. An equal volume, 50 μl, of
luminogenic substrate was mixed with the lysed parasites
and the bioluminescence (in relative light units, RLU) was
measured for 2 sec in a Glomax Multi Detection System
(Promega, UK). Four commercially available (Promega,
UK) luminogenic substrates were used in this study: stan-
dard luciferase (SL) substrate, Bright-Glo™, One-Glo™
and Steady-GloTM.
For the timecourse assay, a 2% trophozoite-stage Dd2luc
culture at 2% HCT was prepared. Five 40 μl samples were
tested with each luminogenic reagent and the biolumines-
cent signal from each sample monitored over 100 mins
immediately thereafter. Mean RLU ± standard deviation
(stdev) were plotted against time. To determine the rela-
tive decay of samples, the RLU measured at each time-
point was expressed as a fraction of the initial mean RLU
with the mean fraction ± stdev plotted against time.
Dynamics of bioluminescence and fluorescence following
drug treatment
A 2% early trophozoite-stage (17-24hpi) Dd2luc culture
at 2% HCT was prepared and divided into 2 ml aliquots;
one for each drug/assay to be tested and a further no-
drug control. At t = 0 hrs, either three 40 μl aliquots
were removed to determine the initial bioluminescent
signal or three 100 μl samples removed to measure the
fluorescent signal (see below). The drug being tested was
added at this time. At the timepoint indicated, samples
of the appropriate volume were removed and the biolumi-
nescent/fluorescent signal measured. The mean ± stdev
fraction of the bioluminescent/fluorescent signal measured
from the drug-treated samples was normalized against the
mean bioluminescent/fluorescent signal from the no-drug
control at the same timepoint.
Bioluminescent signals were measured using the proto-
col described above with the SL substrate. Fluorescent sig-
nals were measured using a standard MSF assay [14].
Specifically, an equal volume of MSF lysis buffer (100 μl of
20 mM Tris (pH 7.5), 5 mM EDTA, 0.008% (w/v) saponin
and 0.08% (v/v) Triton X-100) containing SYBR green I
(1 × final concentration, from 5000x stock supplied by
Invitrogen, UK) was added to 100 μl of Dd2luc aliquoted
onto a black 96-multiwell plate (Greiner, UK). Well con-
tents were homogenized by repeated pipetting and incu-
bated for one hour in the dark at room temperature. The
fluorescent signal, in RLU, was measured using the blue
fluorescent module (excitation 490 nm: emission 510–570
nm) of a Glomax Multi Detection System (Promega, UK).
Measuring IC50 using luciferase and MSF assay formats
Trophozoite-stage cultures of the transgenic line being
tested (100 μl, 2% parasitaemia, 4% HCT, n = 3) wereadded to 96-multiwell plates containing 100 μl of pre-
dosed (five-fold dilution series) complete medium. On
each assay plate, six wells containing 200 μl of 2% para-
sitaemia cell culture (2% HCT) in the absence of drugs
served as a positive control (100%), whereas the same
culture mix in the presence of a 1 μM supralethal dose
of artemether served as a negative growth control (0%).
The outermost wells on each plate contained 200 μl of in-
complete medium to minimize edge effects from evapora-
tion during 48 hr incubation in a gassed (1% O2, 3% CO2,
and 96% N2) chamber at 37°C.
For bioluminescent assays, RLU were measured using
the SL substrate. Irrespective of the assay, the % growth
was calculated as follows: 100x[μ(S) − μ(−)/μ(+) − μ(−)]
where μ(S), μ(+) and μ(−) represent the means for the
sample in question and 100% and 0% controls, respecti-
vely. The % growth was plotted against log10-transformed
drug concentration and the IC50 determined using a non-
linear regression (sigmoidal dose–response/variable slope
equation) in GraphPad Prism v5.0 (GraphPad Software,
Inc., San Diego, CA).
Determination of assay quality parameters
Derivation of the statistical tests of the assay quality
parameters; Z’ score, %CVmax, %CVmin and signal/noise
ratio was as described [26]. The Z’ score was calculated :
Z0 = 1 − [(3σ(+) + 3σ(−))/ μ(+) − μ(−)], where μ(+) and σ(+)
are the mean and stdev of the no-drug positive control,
respectively; μ(−) and σ(−) are the mean and stdev of a
supralethal kill with 1 μM of artemether (negative con-
trol), respectively.%CVmax was calculated: 100x[σ(+)/μ(+)]
and %CVmin: 100x[σ(−)/μ(−)]. The S/N ratio was calcu-
lated: [μ(+) − μ(−)]/σ(−).
Results
Evaluating the parameters of the Pfpcna-luc
bioluminescence assay
The generation of the Pfpcna-luc transgenic parasite
in the Dd2 (CQR) genetic background (Dd2luc) has been
previously described [21]. The haematocrit and para-
sitaemia starting conditions suitable for a 96-multiwell
format assay using trophozoite stage Dd2luc were estab-
lished using a range of parasitaemia (0.5–5%) at three
different haematocrit (HCT; 1,2 and 4%). The standard
luciferase (SL) luminogenic substate was used to meas-
ure bioluminescence in relative light units (RLU). Cor-
relating RLU against parasitaemia for each HCT used
(Figure 1) shows a strong linear relationship (all R2 >
0.97) irrespective of the HCT. Increasing the parasite
number through fold-increases in HCT does initially
(1 to 2% HCT) result in similar fold-increases in RLU;
however, the fold-increase in RLU between 2% and 4%
HCT is markedly reduced due to the quenching effect
of the additional haemoglobin released at these higher
Figure 1 Correlation of luciferase assay activity with
haematocrit and parasitaemia. Luciferase activity (RLU) from
trophozoite stage Dd2luc was plotted over a range of parasitaemias
from cultures at three haematocrit (1, 2 and 4%, see legend). The
mean RLU ± stdev (n = 5) are plotted with a linear regression line
(R2 > 0.97 in all cases).
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trophozoite-stage parasitaemia were selected for all
future experiments. The selection of 2% parasitaemia
balances the effect of kill (2% and below) and growth
(assuming a 2–3 fold increase in parasitaemia) on the
linear response curve.
The absolute signal intensity and time-dependent decay
of RLU generated from a range of commercially available
luminogenic substrates was next explored. The lumino-
genic substrates were added to lysed Dd2luc and the mean
RLU (n = 5) measured over 100 minutes (Figure 2A). TheFigure 2 Absolute and time-dependent decay of luminogenic substra
and an equal volume of the indicated (see key) luminogenic substrate add
each luminogenic substrate (see key) is plotted over 100 minutes. (B) The r
the mean RLU ± stdev as a proportion of the mean RLU at t = 0 mins.Bright-Glo substrate provided the highest initial absolute
signal, some 60–80% higher than those for the SL and
One-Glo substrates and 20-fold higher than that of
Steady-Glo. Following the time-dependent decay of each
luminogenic substrate, determined in terms of absolute
RLU (Figure 2A) or as a fraction of initial RLU (Figure 2B),
shows that the signal from the Steady-Glo substrate
remains essentially unchanged over the 100 minutes as-
sayed, whilst those of Bright-Glo, SL and One-Glo sub-
strates decay to 10%, 22% and 28% of the original signal,
respectively. Importantly, within the first five minutes, a
time in which a 96-multiwell plate can be readily mea-
sured, there is a maximum loss of 10% of the initial RLU
irrespective of the luminogenic substrate chosen.
The effect of choice of luminogenic substrate for the
determination of IC50 values was evaluated using chloro-
quine (CQ) and artemether (ART). Comparison of the
absolute RLU (Figures 3A and 3C) over the range of
drug concentrations tested shows the expected relative
relationship. Normalizing the RLU as a fraction of the
untreated control for each luminogenic substrate gener-
ates overlapping non-linear sigmoidal dose–response
curves that provide essentially identical IC50 values irre-
spective of the substrate chosen (Figures 3B and 3D).
Ten samples of Dd2luc exposed for 48 hrs to either no
drug (100% growth) or a supralethal dose of ART (1 μM,
0% growth) allow the Z’ score, S/N ratio and coefficient
of variation (%CV) assay parameters to be determined
for each luminogenic substrate in a 96-multiwell format
(Table 1). For comparison, the same assay parameters
were determined using the MSF assay (Table 1). These
data indicate that whilst the Z’ scores are essentially the
same for all the assay formats tested, and all formats
would be readily suitable for HTS, there were significanttes. Trophozoite stage Dd2luc (2% parasitaemia, 2% HCT) were lysed
ed. (A) The decay in absolute mean value of RLU ± stdev (n = 5) for
elative decay for each luminogenic substrate is reported by plotting
Figure 3 The effect of luminogenic substrate choice on the determination of IC50 values. Trophozoite stage Dd2
luc (2% parasitaemia,
2% HCT) were incubated for 48 hrs in the presence of the indicated concentration of drug prior to measurement of the absolute mean
RLU ± stdev (n = 3) using (A) chloroquine and (C) artemether. Normalizing these data as a fraction of the controls (% growth) allows a
dose–response curve to be plotted for each luminogenic substrate for (B) chloroquine and (D) artemether. The IC50 values determined for each
luminogenic substrate (see key in Figure 2) are shown.
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strate provides S/N ratios between 469 and 4042 fold
higher than those of the fluorescence-based MSF assay.
As all the luminogenic substrates share a similar and
very low background signal (50–80 RLU), the fold in-
crease in S/N ratio correlates with the initial absolute
RLU generated by each substrate. The low variation
in the maximal signal (100% growth, %CVmax) acrossTable 1 Comparison of assay parameters from
bioluminescence and fluorescence-based assays
Assay reagent Z’score Signal/noise ratio %CVmax %CVmin
Bright-Glo 0.74–0.84 15667–17746 5.2–6.7 14.8–16.2
SL substrate1 0.73–0.81 12853–13609 8.0–8.9 15.5–17.0
One-Glo 0.77–0.86 8936–10030 4.7–6.3 14.3–19.5
Steady-Glo 0.83–0.86 2063–2344 5.6–7.1 17.2–18.6
MSF 0.72–0.79 4.30–4.39 4.0–6.6 2.8–5.8
1Standard luciferase (SL).all the luminogenic substrates demonstrates the robust
performance of the bioluminescence assays in generating
consistent data. The higher %CVmin provided by the bio-
luminescence assays is a direct result of variation of the
very low background signal (50–80 RLU).Bioluminescence is a more dynamic reporter of drug action
The fluorescence and bioluminescence assays of Dd2luc
both monitor DNA replication. MSF directly moni-
tors DNA content and bioluminescence measures the
S-phase-linked induction of expression of DNA replica-
tion proteins. However, the DNA biomarker is much more
stable than the luciferase biomarker, and each is subject to
distinct cellular regulation processes. To explore the effect
of the stability of these different biomarkers, a lethal drug
perturbation was induced and the immediate dynamic
responses of the bioluminescence and fluorescent assays
followed. For the bioluminescence assays, the SL substrate
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ance of signal intensity, stability and relative cost.
Dd2luc was exposed to supralethal doses of drug per-
turbation; kill was induced using 1 μM of the RNA poly-
merase inhibitor Actinomycin D (ActD) or the ribosome
translational elongation inhibitor cyclohexamide (CHX).
Over 8 hrs, samples were harvested and the biolumines-
cent/fluorescent signal measured. In each case, the RLU
measured were expressed as a fraction of the mean RLU
from an untreated control harvested at the same time-
point to compensate for the normal temporal programme
of luc expression over the course of the experiment.
Kill induced by either drug results in decreasing bio-
luminescent/fluorescent signal over the 8 hours assayed
(Figure 4A). Whereas the bioluminescent signal decre-
ased to between 3 and 22% of the untreated control
(square symbols in Figure 4A), the fluorescent signal
only decreased to between 57 and 65% of the untrea-
ted control over the same period (circles in Figure 4A).
Interestingly, the fluorescent signal initially decreased
more on ActD treatment, whereas the bioluminescent
signal was most affected by CHX. These data suggest
that the action of ActD appears to initially reduce Sybr
Green I binding, presumably through low-affinity bind-
ing to a component of double-stranded RNA, with the
inhibition of de novo DNA synthesis by CHX slightly
delayed. The residual 65% of fluorescence even after
8 hours of supralethal drug treatment presumably re-
flects the stability of the nucleic acid biomarker even
after cell death. By contrast, supralethal doses of CHX
rapidly block the de novo synthesis of luciferase and the
induced kill leads to a rapid decline in bioluminescence.
Over the 8 hours of treatment, the bioluminescent signalFigure 4 Exploring the immediate dynamic response of bioluminesce
time-dependent changes in relative RLU (bioluminescent and fluorescence
stage Dd2luc (2% parasitaemia, 2% HCT) exposed to a supralethal 1 μM dos
The fraction of mean RLU ± stdev (n = 3) at each timepoint are shown for
time-dependent changes in mean fraction of luciferase RLU ± stdev (n = 3
artemether (ART), azithromycin (AZ), dihydroartemisinin (DHA) and chloroqdecreases to 3% of the untreated control, with the time-
response curve indicating that the luciferase protein has
a half-life of approximately 1.5 hours in P. falciparum.
The action of ActD appears slightly delayed, presumably
as luc transcript is available for translation prior to cell
death.
Based on the initial dynamic response of the biolu-
minescence assay to ActD and CHX, the effect of anti-
malarial drugs was similarly tested. Four drugs were
selected; dihydroartemisinin (DHA, 20nM), artemether
(ART, 25nM), chloroquine (CQ, 500nM) and azithro-
mycin (AZ, 6 μM) with the concentration of each drug
representing the 3xIC50 dose (see below). The time-
response curves generated provide relative rate-of-kill
data that follows the known relative action of these
drugs (Figure 4B) [10]. The artemisinins ART and DHA
provide the fastest rate of kill. CQ represents an inter-
mediate between the artemisinins and AZ, a drug that
shows a delayed-death phenotype. The killing-effect of
AZ would not be expected to be exerted within the
8 hour time period used here, instead requiring the
parasite to complete at least one full cycle of intraery-
throcytic development [18].
Side by side comparison of bioluminescence v.
fluorescence determination of IC50
As luciferase expression in Dd2luc is temporally linked to
DNA replication, this parasite offers the most appropri-
ate bioluminescence assay for a side by side comparison
with the DNA intercalating action of Sybr Green I in the
MSF assay. To extend the comparison of IC50 derived
from bioluminescence and fluorescence assays using the
Pfpcna-luc cassette, this cassette was also introducednce and fluorescence assays of drug activity. (A) Plot of the
when compared to untreated control) measured from trophozoite
e of actinomycin D (filled symbol) or cyclohexamide (open symbol).
a luciferase assay (square) or MSF assay (circle). (B) Plot of the
) exposed to 3xIC50 doses of the indicated anti-malarial drug;
uine (CQ).
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The Pfpcna-luc cassette was introduced into NF54attB by
bxbI-mediated integration (Figure 5A) as confirmed by
PCR analysis (Figure 5B). To demonstrate that the same
temporal control of Pfpcna was reconstituted over the
luc gene in NF54attB, stage-specific northern blots and
luciferase assays were performed (Figures 5C and 5D).
Taking five timepoints (T1 to T5) that represent major
morphological stages during asexual intraerythrocytic
development (early ring, late ring, early trophozoite, late
trophozoite and schizont, respectively), the expected pat-
terns of temporal steady-state transcript levels and luci-
ferase activity were demonstrated, with the highest levels
for both coinciding with S-phase in late trophozoites
(sample T4) [22].
Using the luciferase transgenic lines Dd2luc and NF54luc,
the IC50s for eight anti-malarial drugs, representing a rangeInt Neo
pINT Pfpcna-luc pla
BSD
attP
attBcg6 5’ cg6 3’
XInt mediated recombination
attLcg6 5’
BSD Luc
P1 P2
P3P1
A
NF54attB
NF54luc
C D
Pfpcna
Luc
T1 T2 T3 T4 T5
Figure 5 Generation of the NF54luc transgenic line. (A) Schematic repre
plasmid into the cg6-attB locus in NF54attB. BSD and Neo represent the dru
position and orientation of oligonucleotide primers (P1 to P3) used to con
Pfpcna-luc plasmid. The top panel shows results of PCR across the cg6-attB
junction (primers P1 and P3) resulting from successful integration in NF54lu
expected across the cg6-attB locus as this is disrupted with the hdhfr drug
Pfpcna and luc transcripts. The expected sizes of the predominant transcrip
timepoints of sampling from early rings, late rings, early trophozoites, late t
sampling of NF54luc (2% parasitaemia, 2% HCT) over T1–T5. The bars represof modes of action, were determined using both bio-
luminescence and MSF assays (Table 2). The parental lines
Dd2attB and NF54attB were included using the MSF assay
alone as a control to explore any effect on IC50 resulting
from the genetic modification with the Pfpcna-luc cas-
sette. Irrespective of the assay format, the IC50s deter-
mined for these drugs were essentially the same. The
differences in IC50 for CQ and quinine (QN) between
Dd2luc and NF54luc reflect known differences in their re-
sistance profiles for these quinolone drugs. Determi-
ning the mean IC50 ratio for Dd2
luc/NF54luc for CQ
gave values of 8.57 and 8.91 for the bioluminescent
and MSF assays, respectively. Similarly, for QN, the
ratios were almost identical; 2.38 and 2.28, and reflect
typical values for these drugs in CQR/CQS parasites.
The IC50 values derived using the MSF assay for the
docking parasite lines Dd2attB and NF54attB were similarlysmid
Cg6 locus 
(P1+P2)
Integration
(P1+P3)
Luc
cg6 3’attR
B
T1 T2 T3 T4 T5
senting the bxbI-integrase (Int) mediated integration of the Pfpcna-luc
g selection markers for blasticidin S and neomycin, respectively. The
firm integration are shown. (B) PCR monitoring of integration of
locus (primers P1 and P2), and the lower panel, PCR across the attL
c. Dd2luc is included as control. In the case of Dd2luc, no product is
selection cassette. (C) Stage-specific northern blot using probes to
ts of 1.8Kb and 2.6Kb, respectively, were found. T1 to T5 represent
rophozoites and schizonts, respectively. (D) Time-course of luciferase
ent mean RLU ± stdev (n = 5) using the standard luciferase substrate.
Table 2 Comparison of IC50 derived from bioluminescence and fluorescence-based assays
Drug1 MSF Luc MSF Luc
Dd2attB Dd2luc Dd2attB NF54attB NF54luc NF54luc
Artemether 12.0 ± 0.5 11.3 ± 0.3 8.4 ± 0.8 12.1 ± 1.3 13.1 ± 0.9 12.2 ± 0.9
Atovaquone 1.9 ± 0.4 1.3 ± 0.6 1.7 ± 0.1 0.7 ± 0.6 0.9 ± 0.2 2.9 ± 0.3
Azithromycin >1580 >1580 >1580 >1580 >1580 >1580
Cloroquine 22.6 ± 2.5 26.4 ± 1.0 18.6 ± 2.5 26.7 ± 1.0 13.2 ± 2.1 21.0 ± 1.3
Dihydroartemisinin 133.0 ± 7.8 125.6 ± 2.4 166.3 ± 7.4 7.9 ± 0.7 14.1 ± 2.2 19.4 ± 1.8
Mefloquine 4.4 ± 0.5 7.8 ± 1.2 6.0 ± 0.4 9.7 ± 1.4 7.1 ± 1.2 5.6 ± 0.3
Quinine 173.5 ± 13.0 157.3 ± 20.0 115.4 ± 9.1 62.6 ± 5.7 69.0 ± 3.2 48.5 ± 4.0
WR99210 nd2 nd nd nd 0.55 ± 0.13 0.48 ± 0.21
1IC50 values (n.3 independent measurements in the triplicate) reported as mean ± standard deviation in nM,
2not done.
Hasenkamp et al. Malaria Journal 2013, 12:58 Page 8 of 10
http://www.malariajournal.com/content/12/1/58unchanged from the MSF assays of the related luc trans-
genic lines.
Discussion
The utility of bioluminescence in single-dose HTS of
small- to medium-sized chemical libraries has been rea-
dily demonstrated, providing evidence for the luciferase
reporter assay as a robust and reliable platform for anti-
malarial drug discovery [16,18,20]. An evaluation of a
range of commercially-available luminogenic substrates
suitable for scale-up of this assay platform are evaluated
here. This evaluations shows that key assay parameters
such as the Z’-score and % coefficient of variation are
essentially the same irrespective of the luminogenic
substrate selected. Whilst Steady-Glo appears to offer
a significant advantage due to its relative signal stabil-
ity, particularly when considering use of 384 or even
1536-microwell plates, this is simply ameliorated through
the use of microinjection devices that deliver substrate im-
mediately prior to detection of the bioluminescent signal.
Thus, the standard luciferase substrate, the only commer-
cial luminogenic substrate investigated here that is not
co-formulated with lysis reagent (and thus less prone to
foaming on microinjection) would perhaps represent the
best choice for scale-up. Critically, however, biolumi-
nescence would appear to offer few advantages over the
current choice of Sybr-Green I fluorescence assay for
single-dose HTS. The advantages offered by the higher
S/N ratio and very low background of bioluminescence,
whilst extremely helpful for ready analysis of the data, are
significantly outweighed by the increased cost of lumino-
genic substrate and the restriction of study to only those
P. falciparum lines that are genetically modified to express
luciferase.
The opportunities for bioluminescence would thus
appear to lie elsewhere. One such area is the exploration
of stage-specific activity of anti-malarial drug action.
Currently, in addition to the late trophozoite-specific
expression of luciferase reported here, P. falciparumtransgenic lines that express peak luciferase levels in ring,
schizont and different gametocyte stages exist [15,17,20].
The advantages in very high S/N ratio reported here, how-
ever, are not as apparent in the studies that describe these
other transgenic parasites. For example, whilst this study
reports S/N ratios between 15667 and 17746 using the
Bright-Glo substrate, the same substrate only provided
S/N ratios up to 430 in a transgenic parasite where the luc
gene is under the control of a Pfhrp2 promoter [20]. These
findings may result from technical issues associated with
choice of luminometer or perhaps, more likely, from a
need to better understand the role of luc flanking se-
quences. Using matched Pfpcna 50 and 30 flanking se-
quences, a complete reconstitution of the absolute and
temporal control of the endogenous gene over the luc re-
porter can be done [21]. This same observation is similarly
true using a second gene, PF0660w, which is expressed in
trophozoite-stage parasites (Hasenkamp et al. submitted).
These findings would suggest that use of matched flanking
sequences from genes subject to high levels of temporally-
linked expression may offer the opportunity to develop a
library of transgenic parasites suitable for the screening of
stage-specific anti-malarial drug activity.
The high rate of luciferase turnover, however, may
offer the most attractive opportunity for assay develop-
ment. Inducing kill using supralethal doses of the trans-
lation inhibitor CHX indicates that luciferase has an
approximate 1.5 hr half-life in P. falciparum. This high
rate of reporter turnover, accompanied by high quantum
yield of light from strong matched regulatory sequences,
may be exploited to facilitate the in vitro investigation of
the immediate dynamics of drug treatment. Rate-of-kill
is a critical determinant of anti-malarial drug action and
ideally this should be as fast as possible [1]. Rapid rate-
of-kill is a specific stated attribute in the target product
profile for a single-exposure radical cure drug, with the
intention of rapidly reducing the parasite burden, and
thus clinical symptoms of disease (www.mmv.org). Rate-
of-kill is typically first characterized during phase IIa
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recently described [10]. As this recrudescence-based
in vitro assay of rate-of-kill assay requires some 21–28 days
post-drug selection to develop the data, the utility of a
more rapid in vitro assay to explore the rate-of-kill of anti-
malarial drugs is potentially of interest in establishing pri-
orities for anti-malarial drug development programmes.
Conclusion
This study provides proof-of-principle data supporting
the application of bioluminescent assays to determine
the relative rate-of-kill of four anti-malarial drugs. The
relative rate-of-kill as judged from bioluminescent assays
is the same as that previously reported from in vivo PRR
and in vitro recrudescence rate-of-kill assays [10]. Critic-
ally, drugs that exhibit the same mode of action show
similar relative rates-of-kill in this novel assay format. Im-
portantly, these assays were performed in a 96-multiwell
plate format over a six-hour window which would suggest
some potential for development into a rapid in vitro rate-
of-kill assay more amenable for scale up.
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